HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Wella

This article was originally published in The Rose Sheet

Executive Summary

Domination and profit agreement with Procter & Gamble is approved at Wella's June 8 annual general meeting in Darmstadt, Germany, giving P&G full control of Wella. Agreement, announced April 26, became effective June 11 after registration with the German commercial register in Darmstadt. Firm will not revise its offer of €72.86 per share for remaining Wella shares, although certain minority shareholders have objected to the price and intend to take the matter to court in Germany CFO Clayt Daly maintained during the Deutsche Bank Global Consumer Conference in Paris June 10. In addition, motion by P&G to reduce the Wella dividend to €.06 for preference shares and €.04 for ordinary shares is approved at the AGM...

Latest Headlines
See All
UsernamePublicRestriction

Register

RS012216

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel